Search

Displaying results 2851 - 2860 of 7284 in total
  1. Drug

    Meluadrine

    go.drugbank.com/drugs/DB20693
    Experimental

    Meluadrine is a small molecule drug. The usage of the INN stem '-drine' in the name indicates that Meluadrine is a sympathomimetic. Meluadrine has a monoisotopic molecular weight of 243.1 Da.

  2. Drug

    Bamirastine

    go.drugbank.com/drugs/DB21186
    Experimental

    Bamirastine is a small molecule drug. The usage of the INN stem '-astine' in the name indicates that Bamirastine is a antihistaminic. Bamirastine has a monoisotopic molecular weight of 527.29 Da.

  3. Drug

    Barmastine

    go.drugbank.com/drugs/DB21253
    Experimental

    Barmastine is a small molecule drug. The usage of the INN stem '-astine' in the name indicates that Barmastine is a antihistaminic. Barmastine has a monoisotopic molecular weight of 483.24 Da.

  4. Drug

    Zanoterone

    go.drugbank.com/drugs/DB21384
    Experimental

    Zanoterone is a small molecule drug. The usage of the INN stem '-terone' in the name indicates that Zanoterone is a antiandrogen. Zanoterone has a monoisotopic molecular weight of 416.21 Da.

  5. Drug

    Elunonavir

    go.drugbank.com/drugs/DB21518
    Experimental

    Elunonavir is a small molecule drug. The usage of the INN stem '-vir' in the name indicates that Elunonavir is a antiviral. Elunonavir has a monoisotopic molecular weight of 1155.44 Da.

  6. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. … [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA.

    Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, ARZOMEBA PISA 500MG/500MG (IMIPENEM+CILASTATINA) POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE
  7. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  8. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.

  9. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.

  10. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin D immune FAB2 (equine), BOTULINUM NEUROTOXIN D IMMUNE FAB2, EQUINE